WEBSep 13, 2024 · PhoreMost Ltd, a leading UK biopharmaceutical company unlocking the next generation of drug targets, has added USD $12 million to its Series B financing, bringing the total raised to over $50 million. The additional investment was led by Parkwalk Advisors, the largest growth EIS fund manager, with participation from existing investors BGF, Dr Jonathan Milner, Amadeus Capital and Astellas ...